Compare FLGC & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGC | ALZN |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.2M |
| IPO Year | 2021 | 2021 |
| Metric | FLGC | ALZN |
|---|---|---|
| Price | $6.71 | $1.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 70.0K | 46.5K |
| Earning Date | 11-05-2025 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,609,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.71 | N/A |
| 52 Week Low | $6.57 | $1.88 |
| 52 Week High | $47.00 | $11.70 |
| Indicator | FLGC | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 30.73 | 32.62 |
| Support Level | $7.10 | $2.10 |
| Resistance Level | $7.55 | $2.27 |
| Average True Range (ATR) | 1.28 | 0.11 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 0.41 | 13.75 |
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.